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ABSTRACT
Objectives: Variceal (VUGIB) and nonvariceal (NVUGIB)
upper gastrointestinal bleeding are prevalent causes of
hospitalization. Cost estimates are needed to determine the
impact of their contemporary treatments (endoscopic hemo-
stasis and high-dose proton pump inhibition). We determined
the costs of upper gastrointestinal bleeding with or without
complications (rebleeding).
Methods: Charges and length of stay (LOS) were obtained
from the United States Nation-wide Inpatient Sample. We
deﬁned NVUGIB using Diagnosis Related Groups, and
VUGIB using International Classiﬁcation of Diseases, Ninth
Revision, Clinical Modiﬁcation codes.
Results: Hospitalization costs with and without complica-
tions were $5632 and $3402 for NVUGIB, and $23,207 and
$6612 for VUGIB, respectively; similarly, mean LOS were
4.4 and 2.7 days, and 15.2 and 3.8 days.
Conclusion: We present hospitalization costs and LOS for
VUGIB and NVUGIB with and without complications. The
reliability of our estimates rests with the size and the national
representativeness of the databases used, and should prove
helpful for cost analyses for UGIB requiring updated national
estimates.
Keywords: cost, nonvariceal, peptic ulcer, variceal, upper
gastrointestinal bleeding.
Introduction
Upper gastrointestinal bleeding (UGIB), which
accounts for approximately 300,000 admissions
yearly, for a total expenditure of $2.5 billion annually
in the United States [1], has undergone signiﬁcant
evolution in management over the past 10 years [2].
Appropriate and accurate determinations of costs are
needed to better assess the cost-effectiveness of new
therapeutic modalities such as endoscopic hemostasis
and intravenous proton pump inhibition [2]. Existing
cost estimates published to date vary widely (from
$2,860 [3] to $24,081 [4] for a hospitalization for
UGIB, and from $8,832 [5] to $61,522 [6] for variceal
ulcer bleeding), because of the use of disparate meth-
odologies and sources of data [7]. We therefore under-
took a study to validly determine clinically relevant
current hospital stay costs for patients admitted with a
diagnosis of UGIB in the United States.
Methods
The charges and length of stay (LOS) per hospitaliza-
tion were obtained from the Nation-wide Inpatient
Sample (NIS2002) database. NIS is sponsored by the
Agency for Health Care Policy and Research and con-
tains two databases. The ﬁrst is a hospital database
providing the characteristics of 995 hospitals in 35
states. The second is an inpatient database on
7,853,982 hospitalizations that does not include phy-
sician fees. We selected hospitalizations of patients
aged 18 years and older who did not die during the
hospital stay. We deﬁned nonvariceal UGIB as hospi-
talizations with a Diagnosis Related Group (DRG) of
gastrointestinal hemorrhage with or without compli-
cations, and with or without comorbidities (DRG 174
and 175). Cases of variceal UGIB were deﬁned using
International Classiﬁcation of Diseases, Ninth Revi-
sion, Clinical Modiﬁcation (ICD9-CM) codes 456.0
and 456.20. These codes regroup patients with a
diagnosis of “esophageal varices with bleeding” and
“esophageal varices in diseases classiﬁed elsewhere,
with bleeding,” respectively. Different methodologies
were used to identify patients with rebleeding (as pre-
viously deﬁned [8]) according to whether they had
experienced an episode of variceal or nonvariceal
UGIB. For nonvariceal UGIB, we used the differentia-
tion provided by the DRGs. Because the ICD9-CM
codes 456.0 and 456.20 do not distinguish patients
with and without rebleeding, we decided to deﬁne
variceal UGIB with rebleeding according to those
patients who have experienced an LOS above an
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empirically chosen threshold. This threshold was
determined by a clinician-expert (AB) after examina-
tion of the bimodal distribution of LOS among
variceal ulcer patients as it appeared in the NIS data-
base. We established a 9-day threshold, assuming that
the second peak of LOS corresponded to a subpopu-
lation of patients with variceal bleeding whose stay
was prolonged because of a complication, which often
is due to rebleeding [9]. The per-diem charges were
computed as the sum of all charges divided by the sum
of all LOS. Because the charges do not reﬂect the
actual cost value of the medical resources used for a
treatment, we used cost-to-charge ratio, which is a
recognized ratio used for converting charges into costs
[7]. We used the conversion rates published by Medi-
care (National Archives and Record Administration)
per state, for both urban and rural areas, while
merging the hospital and inpatient stay databases to
assign the type of hospital (urban or rural) to each
hospitalization. We adopted the perspective of a third-
party payer (i.e., the charges payer), thus not taking
into consideration physician fees. All results were
expressed in 2004 $US using the consumer price index
for medical care, provided by the Department of
Labor.
Results
Twenty percent (1,570,796 records) of the complete
NIS database was used for the cost estimates of non-
variceal UGIB. Because the number of hospitalizations
recorded as variceal UGIB was much less, all valid
cases of variceal UGIB were extracted from the com-
plete database (7,853,982 hospitalizations). As a
result, we selected 19,077 admissions (3,131 with
rebleeding) for nonvariceal UGIB, and 840 (67 with
rebleeding) for variceal UGIB. Estimations of charges,
LOS, and costs are presented in Table 1. Because the
ﬁrst days of a hospitalization typically require more
medical resources, the per-diem can be lower for
patients with longer stays as is the case for complicated
versus uncomplicated variceal UGIB. Except for
rebleeding among patients with variceal UGIB, all
other UGIB hospitalizations presented an LOS
between 2 and 5 days, costing $3000 to $7000. The
hospitalizations of patients with complicated variceal
UGIB lasted much longer (more than 2 weeks on
average) and were associated with a greater mean cost
(more than $23,000) (Table 1). The cost and LOS
attributable to rebleeding were approximately fourfold
higher for variceal UGIB when compared with nonva-
riceal UGIB.
Discussion
Cost and LOS estimates for nonvariceal and variceal
UGIB vary widely in the literature, yet more precise
estimates are required because new treatments have
prompted the publication of many recent cost-
effectiveness analyses [2,8]. Unfortunately, the deter-
mination of actual inpatient costs is difﬁcult, and all
estimates are in fact approximations [7]. In the United
States, costs vary substantially, even within the same
city [7]. The different possible approaches in treating
UGIB, the rapid evolution of technologies, differences
among hospitals, and patient characteristics are all
determinants of costs and LOS. Additionally, adopted
costing methods are not uniform. Some publications
have used large databases [3,4,8,10], which could be
representative of a national average, while others base
their calculations only on patient cohorts from single
centers or small groups of local institutions [6,9],
which may not be as generalizable. Some articles refer
to means [3,4,6,8–10], others to median costs [10],
and yet others to both [11]. Because the costs attrib-
utable to the management of UGIB are not normally
distributed (a few hospitalizations utilize a very large
quantity of medical resources), a choice has to be made






Without CC ICD9 = 456.0;
456.20 LOS <10
With CC ICD9 = 456.0;
456.20 LOS 10
N 3,131 15,946 773 67
Female % 49 52 33 36
Mean age 65 71 57 59
Mean LOS 2.7 (1.9) 4.4 (3.6) 3.8 (1.9) 15.2 (5.5)
Per-diem charges 3,647 (3,276) 3,656 (3,814) 4,991 (4,354) 4,508 (2,953)
Per-diem cost 1,255 (968) 1,287 (1,176) 1,740 (1,445) 1,526 (956)
Per stay charges 9,883 (8,877) 16,006 (16,695) 18,964 (16,545) 68,558 (44,919)
Per stay costs 3,402 (2,622) 5,632 (5,149) 6,612 (5,488) 23,207 (14,538)
Values in parentheses are standard deviations.
The dead are excluded.
The rebleeding categories are deﬁned by the CC (CC = complications/comorbidity).
All costs are expressed in 2004 $US.
DRG, Diagnosis Related Group; ICD9, International Classiﬁcation of Diseases, Ninth Revision; LOS, length of stay; NVUGIB, nonvariceal upper gastrointestinal bleeding; UGIB, upper
gastrointestinal bleeding;VUGIB, variceal upper gastrointestinal bleeding.
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as to which summary measure of central trend is used.
The mean appears to be more appropriate, as the
median ignores the 50% most expensive hospitaliza-
tions, which are not uncommon when considering the
prevalence of rebleeding, a clinically important entity.
Indeed, for UGIB, admissions with complications are
an inherent component of the disease and affect a
signiﬁcant proportion of patients with the condition
[9], with a resultant signiﬁcant cost impact. We thus
chose to consider the mean in order not to underesti-
mate costs. A more important source of heterogeneity
arises from the disparate use of either charges [6,8] or
costs [4,10]. We presented estimates of both charges
and costs, using cost-to-charge ratios, as previously
carried out [7]. Costs and LOS associated with
rebleeding or complications are difﬁcult to identify,
and thus rarely cited [6,8]. We used diagnostic codes
wherever possible; where this information was not
available, we adopted an arbitrary and pragmatic deﬁ-
nition based on the assumption that, among patients
with variceal bleeding, a second frequency peak of
longer LOS is largely determined by a signiﬁcant pro-
portion of patients with rebleeding [9]. Although
reﬁnement of this working deﬁnition should ideally be
sought, the validity of our cost estimations resides
principally in the size of the source of data and its
national representativeness, because NIS is indeed the
largest all-payer inpatient care database publicly avail-
able in the United States. Moreover, our estimates of
costs and LOS for a UGIB hospitalization are within
the broad range of US estimates published in the last
10 years [3–6].
Conclusion
We have determined valid, broadly representative costs
attributable to hospitalizations for variceal and non-
variceal UGIB, including those with and without
rebleeding. These references may serve as a common
standard that may populate in a more meaningful and
standardized fashion the assumptions used in future
cost-effectiveness analyses assessing the management
of patients with UGIB.
Source of ﬁnancial support: Dr. Alan Barkun is a research
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